Takeda Pharmaceutical Company Limited

Equities

4502

JP3463000004

Market Closed - Japan Exchange Other stock markets 02:30:00 2025-06-24 EDT			5-day change	1st Jan Change
4,365.00 ^JPY	+1.89%		+0.67%	+4.40%

06-10	Takeda Pharmaceutical Company Limited - Special Call
06-09	Keros Therapeutics Shareholder Seeks $475 Million Dividend; Threatens to Nominate New Directors at 2026 Annual Meeting	MT

Takeda Pharmaceutical Company Limited, 2024 Earnings Call, May 09, 2024

Published on 2024-05-09 at 06:00

Presenter Speech
Christopher David O'Reilly (Executives)

Thank you very much for your participation in the conference call for the financial results for fiscal year 2023 of Takeda Pharmaceutical

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited - Special Call	06-10
Keros Therapeutics Shareholder Seeks $475 Million Dividend; Threatens to Nominate New Directors at 2026 Annual Meeting	06-09	MT
Trump's tariffs and threatened trade actions	06-04	RE
Trump's tariffs and threatened trade actions	06-04	RE
European Commission Approves Adcetris®? (Brentuximab Vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage Iib/Iii/Iv Hodgkin Lymphoma in Combination with Ecadd	06-03	CI
Takeda Pharmaceutical Receives European Commission Approval for Adcetris Regimen to Treat Hodgkin Lymphoma	06-03	MT
Takeda to Withdraw, Replace Shelf Registration to Support Incentive Plan	06-03	MT
Takeda Pharmaceutical Says Co Will File Shelf Registration Statement In Japan	06-02	RE
Protagonist Therapeutics, Inc. and Takeda Announce Asco Plenary Presentation Highlighting Full 32-Week Results from Phase 3 Verify Study of Rusfertide	06-02	CI
Protagonist Therapeutics, Takeda's Potential Polycythemia Vera Drug Meets Primary Endpoint	06-02	MT
Takeda Presents Clinical Data of Polycythemia Vera Treatment at Oncology Conference	06-02	MT
Trump's tariffs and threatened trade actions	05-30	RE
Veeva Systems Shares Rise After Q1 Results Top Expectations	05-29	MT
Trump's tariffs and threatened trade actions	05-28	RE
Xoma Royalty Acquires Mezagitamab Royalty, Milestone Rights From BioInvent	05-27	MT
GLP-1 diabetes drugs like Ozempic may modestly reduce cancer risks	05-22	RE
Health Rounds: Older diabetes drugs appear to slow prostate cancer in small study	05-21	RE
Takeda Announces The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1	05-14	CI
Takeda Pharmaceutical Gets UK Drug Regulator's Approval for CTTP Drug	05-14	MT
UK's MHRA Approves RADAMTS13 For Congenital Thrombotic Thrombocytopenic Purpura	05-12	RE
Asian Equities Traded in the US as American Depositary Receipts Surge in Monday Trading	05-12	MT
Donald Trump deals another blow to Big Pharma	05-12
Trump's tariffs and threatened trade actions	05-12	RE
Japan's Nikkei ends higher on US-China trade deal hopes	05-12	RE
Jefferies Adjusts Takeda Pharmaceutical's Price Target to 5,100 Yen From 5,500 Yen, Keeps at Buy	05-09	MT